Across TCGA pan-cancer cohorts, SHOX Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SHOX data layer compared with 21 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SHOX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SHOX expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
HNSC, COAD, and SARC are the cancer types where SHOX Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.